Suppliers and packagers for CELEXA

CELEXA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	CELEXA	citalopram hydrobromide	TABLET;ORAL	020822	NDA	Allergan, Inc.	0456-4010-01	100 TABLET, FILM COATED in 1 BOTTLE (0456-4010-01)	1998-07-17
Abbvie	CELEXA	citalopram hydrobromide	TABLET;ORAL	020822	NDA	Allergan, Inc.	0456-4020-01	100 TABLET, FILM COATED in 1 BOTTLE (0456-4020-01)	1998-07-17
Abbvie	CELEXA	citalopram hydrobromide	TABLET;ORAL	020822	NDA	Allergan, Inc.	0456-4040-01	100 TABLET, FILM COATED in 1 BOTTLE (0456-4040-01)	1998-07-17

Suppliers and packagers for CELEXA

Last updated: May 25, 2026

Celexa (citalopram) suppliers: API, finished-dose, and contract manufacturing landscape by geography

Executive summary: Celexa is citalopram (SSRI). In the US, Celexa is marketed by Allergan/Forest (Actavis/Teva-era corporate lineage in filings) and is now largely generically penetrated in most markets. For “suppliers,” the practical supply-chain questions split into (1) API manufacturers (citalopram HBr/hemihydrate salt, where applicable), (2) finished-dose manufacturers of generic citalopram tablets, and (3) contract manufacturing/labelers that appear on drug product listings and ANDA dossiers. Without a specified market (US/EU/UK/Canada) and dosage strength (e.g., 10 mg, 20 mg, 40 mg), the supplier set is not uniquely determinable from a single authoritative list.

Who supplies Celexa (citalopram) tablets in the US today?

Featured snippet answer: In the US, Celexa’s brand supply is backed by the original NDA holder’s manufacturing network, but market supply for citalopram tablets is dominated by multiple generic manufacturers listed in the FDA’s drug approval and prescription drug product landscape.

Brand vs. generic supply

• Brand Celexa (citalopram): manufactured under the NDA’s approved drug product manufacturing authorizations.
• Generic citalopram tablets: supplied by multiple ANDA holders and their contract manufacturing sites; labelers change by strength and approved facility.

What to check to identify “suppliers”

• FDA Orange Book entry for each strength (10 mg, 20 mg, 40 mg) to get the list of approved products and their applicants.
• NDC product records to identify marketing company and corresponding manufacturing/labeling sites.
• ANDA labels and facilities typically require cross-checking because ANDA applicants may use different manufacturing contractors over time.

What are the key API suppliers for citalopram (Celexa active ingredient)?

Featured snippet answer: Citalopram API is produced by multiple global fine-chemical and API manufacturers, with supply depending on salt form specifications and regulatory status (DMF/CEP where used).

API supply-chain structure

• API manufacturer (DMF holder or CEP holder for EU use)
• API salt/form used for tablet manufacturing (e.g., citalopram hydrobromide forms)
• Formulation and tableting manufacturer (granulation, compression, coating, packaging)
• Quality systems aligned to ICH stability and cGMP expectations

How citalopram API supplier selection typically works

• Generic entrants and contract manufacturers buy API under qualified supply agreements.
• Switching API supplier is managed via comparability and regulatory reporting paths tied to the ANDA change-control history.

Which companies manufacture generic citalopram tablets that compete with Celexa?

Featured snippet answer: The generic market includes multiple ANDA-approved generic citalopram tablets across common strengths, supplied by different manufacturers and labelers.

Company types you will see

• ANDA holder (marketing authorization holder)
• Manufacturing site (drug product manufacturing facility)
• Sometimes a contract manufacturing network via subcontracted coating, packaging, or compression

Why “supplier” varies by strength

• Even within one molecule, multiple ANDA approvals exist by strength.
• Each strength can map to different manufacturing sites.

How do you identify Celexa suppliers by NDC and strength?

Featured snippet answer: Use the NDC directory/NDC codes for each strength to map the marketing labeler and the manufacturing facility.

Operational mapping workflow (used in sourcing diligence)

1. Pull the NDCs for Celexa and for the generic equivalents you care about.
2. Map each NDC to:
   • Labeler (marketing company)
   • Manufacturer (or “manufacturing”/“relabeler” fields)
3. Cross-check with the Orange Book to confirm which products are officially listed for substitution/exclusivity status.

What is the Orange Book status of Celexa (citalopram) and how does it affect sourcing?

Featured snippet answer: Celexa’s brand exclusivity has ended; the product is subject to generic substitution dynamics and ongoing Orange Book listings for related patents (if any remain in force for specific aspects).

What this means for suppliers

• If patents and exclusivity no longer block generic entry, sourcing shifts to:
  • generic tablet supply continuity
  • facility qualification and supply assurance
  • price-led procurement and multi-sourcing strategies

Which Celexa contract manufacturing suppliers appear in drug product listings?

Featured snippet answer: Contract manufacturing vendors generally appear indirectly through:

• the ANDA applicant’s label/manufacturer address,
• the NDC manufacturing site,
• and occasional facility references in ANDA or litigation filings.

Common diligence checkpoints

• cGMP facility status
• inspection history risk screens
• batch continuity for scale-up and supply planning
• packaging line capacity (bottles vs. unit-dose formats)

What patent and exclusivity events affect Celexa generic supply timing?

Featured snippet answer: For citalopram, broad brand exclusivity is not a current primary barrier; current supply competition is driven by ANDA approvals and any remaining patent or exclusivity overlays tied to specific formulation or packaging claims, if any.

Supplier implication

• When no longer covered by patent exclusivity, procurement focuses on:
  • number of approved ANDA products,
  • manufacturing redundancy (sites and markets),
  • and supply disruptions.

How strong is the patent estate for Celexa and does it constrain supplier options?

Featured snippet answer: Celexa’s core molecule is long out of active brand exclusivity in most jurisdictions; constraints on suppliers depend on any remaining, specific patents (formulation, method, process) that could affect particular generic product designs.

Commercial reality

• Even with some patent remnants, the tablet market often has enough approved alternatives to avoid single-source risk.

What generic entry risks exist for citalopram tablets versus Celexa?

Featured snippet answer: Key risks are not “brand-blocking” patents at this stage in most markets; they are more operational and regulatory:

• facility shutdowns,
• inspection outcomes,
• recall history,
• API supply constraints,
• and pricing volatility.

Commercial landscape: who can supply citalopram tablets at scale?

Featured snippet answer: At scale, supply is typically provided by:

• multinational generic companies,
• large regional generics with tablet manufacturing footprints,
• and contract manufacturing networks supporting multiple ANDA labelers.

How to build a resilient supplier list

• Use multiple labelers per strength
• Map each to at least two manufacturing sites where possible
• Require supply continuity commitments in procurement

Key takeaways

• Celexa is citalopram, and in most markets supply is dominated by generic citalopram tablet manufacturers rather than brand-only sourcing.
• “Suppliers” must be defined as either API suppliers or finished-dose manufacturers. The supplier set changes by strength, jurisdiction, and NDC labeler/manufacturer mapping.
• The fastest high-confidence approach for real sourcing is to use Orange Book listings (product approvals by strength) and NDC records (labeler and manufacturing site), then confirm via cGMP and supply continuity checks.

FAQs

1. How do I find the manufacturer of a specific Celexa strength using NDC?
   Use the NDC record to map the labeler/manufacturer fields, then cross-check the strength’s Orange Book entry.

2. Are citalopram API suppliers the same across all generic citalopram tablets?
   No. Generic labelers and manufacturers qualify specific API sources, and API suppliers can vary by site and change-history.

3. Which filings reveal citalopram tablet contract manufacturing facilities?
   ANDA product labeling/manufacturer sections and NDC manufacturing site data typically identify facilities used for commercial batches.

4. Does Celexa face ongoing patent barriers that limit generic suppliers?
   In practice, generic substitution has proceeded broadly; any constraints depend on any remaining, specific patents tied to particular product features.

5. What are the main causes of supply disruption in citalopram tablet markets?
   Drug product manufacturing capacity limits, facility inspection outcomes, API supply issues, and packaging-line constraints.

References (APA)

No specific supplier names or facility identifiers are provided because the underlying FDA Orange Book and NDC mapping records for Celexa/citalopram by strength were not provided in the prompt, and a complete, accurate supplier list cannot be produced without those exact records.